C
Chantale Bernatchez
Researcher at University of Texas MD Anderson Cancer Center
Publications - 158
Citations - 9406
Chantale Bernatchez is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Immunotherapy & Melanoma. The author has an hindex of 37, co-authored 136 publications receiving 6200 citations. Previous affiliations of Chantale Bernatchez include Laval University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng,Jie Qing Chen,Chengwen Liu,Shruti Malu,Caitlin Creasy,Michael T. Tetzlaff,Chunyu Xu,Jodi A. McKenzie,Chunlei Zhang,Xiaoxuan Liang,Leila Williams,Wanleng Deng,Guo Chen,Rina M. Mbofung,Alexander J. Lazar,Carlos A. Torres-Cabala,Zachary A. Cooper,Pei-Ling Chen,Trang N. Tieu,Stefani Spranger,Xiaoxing Yu,Chantale Bernatchez,Marie-Andree Forget,Cara Haymaker,Rodabe N. Amaria,Jennifer L. McQuade,Isabella C. Glitza,Tina Cascone,Haiyan S. Li,Lawrence N. Kwong,Timothy P. Heffernan,Jianhua Hu,Roland L. Bassett,Marcus Bosenberg,Scott E. Woodman,Willem W. Overwijk,Gregory Lizée,Jason Roszik,Thomas F. Gajewski,Jennifer A. Wargo,Jeffrey E. Gershenwald,Laszlo Radvanyi,Michael A. Davies,Patrick Hwu +43 more
TL;DR: It is demonstrated that loss of PTEN in tumor cells in preclinical models of melanoma inhibits T cell-mediated tumor killing and decreases T-cell trafficking into tumors, and support the rationale to explore combinations of immunotherapies and PI3K-AKT pathway inhibitors.
Journal ArticleDOI
Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
Jianjun Gao,Lewis Zhichang Shi,Hao Zhao,Jianfeng Chen,Liangwen Xiong,Qiuming He,Tenghui Chen,Jason Roszik,Chantale Bernatchez,Scott E. Woodman,Pei Ling Chen,Patrick Hwu,James P. Allison,Andrew Futreal,Jennifer A. Wargo,Padmanee Sharma +15 more
TL;DR: It is demonstrated that patients identified as non-responders to anti-CTLA-4 (ipilimumab) have tumors with genomic defects in IFN-γ pathway genes, demonstrating the importance of tumor genomic data, especially IFn-γ related genes, as prognostic information for patients selected to receive treatment with immune checkpoint therapy.
Journal ArticleDOI
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Livnat Jerby-Arnon,Parin Shah,Michael S. Cuoco,Christopher Rodman,Mei-Ju Su,Johannes C. Melms,Rachel Leeson,Abhay Kanodia,Shaolin Mei,Jia-Ren Lin,Shu Wang,Bokang Rabasha,David Liu,Gao Zhang,Claire Margolais,Orr Ashenberg,Patrick A. Ott,Elizabeth I. Buchbinder,Rizwan Haq,F. Stephen Hodi,Genevieve M. Boland,Ryan J. Sullivan,Dennie T. Frederick,Benchun Miao,Tabea Moll,Keith T. Flaherty,Meenhard Herlyn,Russell W. Jenkins,Rohit Thummalapalli,Monika S. Kowalczyk,Israel Cañadas,Bastian Schilling,Bastian Schilling,Adam N.R. Cartwright,Adrienne M. Luoma,Shruti Malu,Patrick Hwu,Chantale Bernatchez,Marie Andrée Forget,David A. Barbie,Alex K. Shalek,Itay Tirosh,Peter K. Sorger,Kai W. Wucherpfennig,Eliezer M. Van Allen,Dirk Schadendorf,Bruce E. Johnson,Asaf Rotem,Asaf Rotem,Orit Rozenblatt-Rosen,Levi A. Garraway,Charles H. Yoon,Charles H. Yoon,Benjamin Izar,Aviv Regev +54 more
TL;DR: A resistance program expressed by malignant cells that is associated with T cell exclusion and immune evasion is identified, and this study provides a high-resolution landscape of ICI-resistant cell states, identifies clinically predictive signatures, and suggests new therapeutic strategies to overcome immunotherapy resistance.
Journal ArticleDOI
Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.
Tina Cascone,Jodi A. McKenzie,Rina M. Mbofung,Simone Punt,Zhe Wang,Chunyu Xu,Leila Williams,Zhiqiang Wang,Christopher A. Bristow,Alessandro Carugo,Michael Peoples,Lerong Li,Tatiana Karpinets,Lu Huang,Shruti Malu,Caitlin Creasy,Sara E. Leahey E. Leahey,Jiong Chen,Yuan Chen,Helen Pelicano,Chantale Bernatchez,Y.N. Vashisht Gopal,Timothy P. Heffernan,Jianhua Hu,Jing Wang,Rodabe N. Amaria,Levi A. Garraway,Peng Huang,Peiying Yang,Ignacio I. Wistuba,Scott E. Woodman,Jason Roszik,R. Eric Davis,Michael A. Davies,John V. Heymach,Patrick Hwu,Weiyi Peng +36 more
TL;DR: It is demonstrated that tumor glycolysis is associated with the efficacy of ACT and the glycolynsis pathway is identified as a candidate target for combinatorial therapeutic intervention.
Journal ArticleDOI
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients
Laszlo Radvanyi,Chantale Bernatchez,Minying Zhang,Patricia S. Fox,Priscilla W. Miller,Jessica Ann Chacon,Richard Wu,Gregory Lizée,Sandy Mahoney,Gladys Alvarado,Michelle R. Glass,Valen E. Johnson,John McMannis,Elizabeth J. Shpall,Victor G. Prieto,Nicholas Papadopoulos,Kevin B. Kim,Jade Homsi,Agop Y. Bedikian,Wen-Jen Hwu,Sapna Pradyuman Patel,Merrick I. Ross,Jeffrey E. Lee,Jeffrey E. Gershenwald,Anthony Lucci,Richard E. Royal,Janice N. Cormier,Michael A. Davies,Rahmatu Mansaray,Orenthial J. Fulbright,Christopher Toth,Renjith Ramachandran,Seth Wardell,Audrey M. Gonzalez,Patrick Hwu +34 more
TL;DR: The results indicate that the immunotherapy with expanded autologous TIL is capable of achieving durable clinical responses in patients with metastatic melanoma and that CD8+ T cells in the infused TIL, particularly differentiated effectors cells and cells expressing BTLA, are associated with tumor regression.